Skytrofa® (lonapegsomatropin-tcgd) – Expanded indication
July 28, 2025 - Ascendis Pharma announced the FDA approval of Skytrofa (lonapegsomatropin-tcgd), for the replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD).